Novartis to Fund US Commercialization of CML Companion Dx on Cepheid's GeneXpert System
October 14, 2010
Novartis to Fund US Commercialization of CML Companion Dx on Cepheid's GeneXpert System
The deal is expected to aid physicians in managing Ph+ CML patients treated with Novartis' Gleevec, and allows Cepheid to expand the test menu for its PCR-based GeneXpert platform, potentially driving additional sales of the system.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Luminex Leveraging Advanced Liquid Logic Alliance to Develop Field-based MDx/Immunoassay System
May 16, 2013 / PCR Insider - Spain's Stat-Diagnostica Aims to Market Near-patient IVD System in Europe, US in 2015
May 16, 2013 / PCR Insider - UW Researchers Commercializing Nanotip Device for DNA Isolation; Exploring Tech for POC Dx
May 16, 2013 / PCR Insider - People in the News: New Hires at RainDance; DxInsights Names Knowlden Executive Director
May 16, 2013 / PCR Insider - Royalties Drive up GeneNews Q1 Revenues Sharply
May 16, 2013 / GenomeWeb Daily News